^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
MA01.07 - Prognostic Value of STK11 & KRAS Mutations and irAE Incidence in Response to Immunotherapy in Hispanics: A Multicenter Analysis
Published date:
08/18/2021
Excerpt:
CONTRADICTING EVIDENCE: Here, we present a multicenter analysis of the predictive value of STK11, KRAS, and irAEs with a subset analysis based on ethnicity performed for the first time. Patients with stage IIIB-IV NSCLC who were treated with ICIs...Interestingly, patients with both STK11 and KRAS co-mutations (S/K) in our populations had significantly improved PFS compared to patients with STK11 mutation alone (S) (16.1m vs. 4.1m, p=0.031) with similar trend with OS (32.3m vs. 21.8m, p=0.21)...concomitant STK11 and KRAS mutations were associated with significantly improved PFS with a positive trend in OS.
Source:
Title:
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Published date:
09/03/2020
Excerpt:
KRASm/STK11m double mutations were associated with worse OS and PFS outcomes versus KRASwt/STK11wt with IO and chemotherapy, similar to the single mutation (STK11m vs STK11wt) findings.
Secondary therapy:
Chemotherapy
DOI:
10.1371/journal.pone.0238358
Source:
Title:
Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.
Published date:
05/13/2020
Excerpt:
...In the combined cohort (discovery+validation), STK11m was associated with significantly worse outcomes to ICI among KRASm cases: ORR 10.2% vs 30.7%, P < 0.001; median progression-free survival (mPFS): 2.0 vs 4.8 months (mo), HR:0.49 [95%CI:0.39-0.61], P < 0.0001; median overall survival (mOS): 6.1 vs 16.9 mo, HR:0.50 [95%CI:0.39-0.63], P < 0.0001.
DOI:
10.1200/JCO.2020.38.15_suppl.e14511
Source:
Title:
Serine/threonine kinase 11 (STK11) mutations and immunotherapy resistance in patients with non-small cell lung cancer.
Published date:
05/13/2020
Excerpt:
...Pts in SKM and SKMP groups had worse outcomes; however, not all the P values were significant. The presence of STK11 mut were associated with shorter OS/PFS in NSCLC pts treated with CPIs, proving its utility as a negative predictive marker. This can be enhanced combining STK11 and KRAS mut and possibly adding PD-L1 (-).
DOI:
10.1200/JCO.2020.38.15_suppl.e15055
Source:
Title:
Genomic alterations profiling by liquid biopsy and their association to immune checkpoints inhibitors (ICI) response in a cohort of non-small cell lung cancer (NSCLC) patients.
Published date:
05/13/2020
Excerpt:
mPFS in patients harboring KRAS mutations was 4.9 m ( vs 10.1 m in patients without KRASmut, logrank test p-value = 0.031) and 4.1 m in those patients with STK11 mutations (vs 9.5 m in patients without STK11mut, logrank test p-value = 0.034). Additionally, mutations in both genes were also associated to statistically significant shorter mPFS 3.9 m vs 9.5 m (logrank test p-value < 0.01).
DOI:
10.1200/JCO.2020.38.15_suppl.e21524
Source:
Title:
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
Excerpt:
The presence of KRAS/STK11 co-mutation and KRAS/STK11/TP53 co-mutation affected OS only in patients treated with ICIs (HR =10.936, 95% CI: 2.337-51.164, P=0.002; HR =17.609, 95% CI: 3.777-82.089, P<0.001, respectively)
DOI:
10.21037/tlcr-20-674
Source:
Title:
Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer
Excerpt:
Forty-one patients with STK11-mutated NSCLC seen in our Thoracic oncology clinic with available next-generation sequencing tumor data were included in the analysis….In TCGA survival analysis, tumors with STK11 mutation with or without KRAS co-mutation were associated with worse survival (P<0.05)...
DOI:
10.21037/jtd-21-1377
